Showing results (511-520 of 673) with videos related to

Sort By:
Pageof 68
The Annals of Pharmacotherapy|April 19, 2012
Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonatesKristi Reynolds, Hema N Viswanathan, Cynthia D O'Malley, et al.
The Lancet. Haematology|December 25, 2017
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trialClaire N Harrison, Alessandro M Vannucchi, Uwe Platzbecker, et al.
BMJ Open|May 24, 2025
Cohort profile: AMBulatoRy blOod preSsure in older adults (AMBROSIA) and AMBROSIA-HOMEKristi Reynolds, Christopher Barrett Bowling, Kimberly Cannavale, et al.
British Journal of Haematology|March 22, 2021
Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centrePaul Deschamps, Mufaddal Moonim, Deepti Radia, et al.
Blood|December 17, 2009
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasmPhilip A Beer, François Delhommeau, Jean-Pierre LeCouédic, et al.
Thorax|January 16, 2016
Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPDC Echevarria, J Steer, K Heslop-Marshall, et al.
Journal of Thoracic Disease|May 13, 2020
Manometry performed at indwelling pleural catheter insertion to predict unexpandable lungPaul J Halford, Rahul Bhatnagar, Paul White, et al.
International Journal of Laboratory Hematology|April 15, 2009
British Society for Haematology, slide session, annual scientific meeting, Glasgow, 2008C V Hutchinson, J Burthem, M Bisland, et al.
Thorax|February 26, 2017
The PEARL score predicts 90-day readmission or death after hospitalisation for acute exacerbation of COPDC Echevarria, J Steer, K Heslop-Marshall, et al.
Experimental Hematology & Oncology|September 18, 2015
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosisMary Frances McMullin, Claire N Harrison, Dietger Niederwieser, et al.
Pageof 68